Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc.

Bullboard Posts

Comment by highoutputon Apr 18, 2020 6:47pm

133 Views

Post# 30925995

RE:Dudes, I'm anticipating that we will be seeing some great

Love the enthusiasm but you literally have no idea what you're talking about.

You are anticipating that we will see good news? WHat makes you think that? Do you have insider information? And what if it doesn't come? Will you just keep posting that good news is on the way until they finally post something? Might as well go play roulette.

I want to see this company do well but man you're like a broken record.

Bullboard Posts

Understanding tax loss season and the “Santa Claus rally”